Viz.ai fills a specific role in hospital care: real-time imaging triage, not general clinical reference. The system runs in the background of radiology workflows, analyzes CT scans, EKGs, and echocardiograms as they are acquired, and alerts care teams when critical findings are detected. With over 50 FDA-cleared algorithms, coverage includes stroke (large vessel occlusion), pulmonary embolism, aortic dissection, intracranial hemorrhage, cervical spine fractures, and more.
The impact is strongest in time-sensitive pathways. Peer-reviewed studies show reduced door-to-treatment times for thrombectomy in stroke workflows, and simultaneous team alerts can shorten handoff delays. Main limitation: this is still a specialized infrastructure product, so it does not replace bedside CDS functions such as drug dosing support, evidence search, or broad differential generation.
Viz.ai closed 2025 with record scale, achieving profitability in its healthcare business while expanding into nearly 2,000 hospitals. The platform processes millions of scans annually. Enterprise pricing means individual physicians don't purchase Viz.ai directly — it's a hospital infrastructure tool, typically integrated with PACS and deployed across radiology, neurology, cardiology, and emergency departments.
This review evaluates Viz.ai exclusively for its radiology applications. As a specialized imaging AI platform rather than a general clinical decision support tool, it was not included in our overall CDS rankings. Within radiology, it remains one of the most mature implementations of AI-assisted imaging triage available today.